Solara Active Pharma Sciences Ltd Partly Paidup

SOLARAPP1 Stock Summary · May 2026

The call delivered a message of operational rebound, with management citing Q4 as the strongest quarter in eight, reporting revenue of INR 392 crore and a 170‑basis‑point improvement in gross margin to 47%, supporting EBITDA just above INR 61 crore (~16% margin). Management’s tone was disciplined and execution‑focused: they reiterated that the core base business is the primary growth and profitability engine and will be prioritized over the loss‑making ibuprofen segment, while pursuing incremental debottlenecking to capture operating leverage from roughly 70% plant utilization without major new capex. At the same time they acknowledged clear tensions — an ongoing ibuprofen strategic review (bankers appointed, decision expected by H1 FY27) is a material drag on consolidated results and has delayed a polymers carve‑out, and a mothballed Vizag facility continues to carry fixed costs as options are evaluated. Near term, leadership declined numeric FY27/28 guidance but expressed confidence Q4 could mark the start of sustained improvement and highlighted priorities of seeding the base business, improving operations, optimizing working capital and restoring balance‑sheet strength toward a debt‑free target by FY29.